-Kit immunoexpression delineates a putative endothelial progenitor cell population in developing human lungs. Am J Physiol Lung Cell Mol Physiol 306: L855-L865, 2014. First published February 28, 2014 doi:10.1152/ajplung.00211.2013.-Expression of c-Kit and its ligand, stem cell factor (SCF), in developing human lung tissue was investigated by immunohistochemistry. Twentyeight human fetal lungs [age range 13 to 38 gestational wk (GW)] and 12 postnatal lungs (age range 1-79 yr) were evaluated. We identified c-Kit ϩ cells in the lung mesenchyme as early as 13 GW. These mesenchymal c-Kit ϩ cells in the lung did not express mast cell tryptase or ␣-smooth muscle actin. However, these cells did express CD34, VEGFR2, and Tie-2, indicating their endothelial lineage. Three-dimensional reconstructions of confocal laser scanning images revealed that c-Kit ϩ cells displayed a closed-end tube formation that did not contain hematopoietic cells. From the pseudoglandular phase to the canalicular phase, c-Kit ϩ cells appeared to continuously proliferate, to connect with central pulmonary vessels, and finally, to develop the lung capillary plexus. The spatial distribution of c-Kitand SCF-positive cells was also demonstrated, and these cells were shown to be in close association. Our results suggest that c-Kit expression in early fetal lungs marks a progenitor population that is restricted to endothelial lineage. This study also suggests the potential involvement of c-Kit signaling in lung vascular development. c-Kit; endothelial cells; lung development C-KIT, A TRANSMEMBRANE TYROSINE kinase receptor, and its ligand, stem cell factor (SCF), exhibit a diverse range of biological functions. The binding of SCF to c-Kit induces receptor dimerization and triggers activation of downstream intracellular signaling, including the PI3K, Jak/STAT, and Ras/Erk pathways, which promote cell survival, gene transcription, and mitogenesis, respectively (21). In addition to cellular functions, the involvement of c-Kit signaling in organ development has also been described (22, 23, 26, 34) , indicating important roles for c-Kit signaling in tissue homeostasis. Along with these reports, c-Kit expression has been demonstrated in various tissue-specific stem cells (5, 21) that are considered to be responsible for tissue homeostasis and fetal development (11, 19) . Exogenous administration of c-Kit ligand, SCF, is also known to induce repair of injured tissues (3, 15, 31, 43) . Although limited evidence for it exists, previous investigations have demonstrated an association of c-Kit signaling with lung development and alveolar structural maintenance (6, 24). Despite the substantial importance of c-Kit and its downstream signaling in tissue maintenance, previous studies did not employ c-Kit as a lung stem cell marker because the majority of c-Kit ϩ cells in adult human lungs have been considered to be bone marrow-derived progenitor cells (28, 40) .
have demonstrated an association of c-Kit signaling with lung development and alveolar structural maintenance (6, 24) . Despite the substantial importance of c-Kit and its downstream signaling in tissue maintenance, previous studies did not employ c-Kit as a lung stem cell marker because the majority of c-Kit ϩ cells in adult human lungs have been considered to be bone marrow-derived progenitor cells (28, 40) .
Recently, Kajstura et al. demonstrated the existence of multipotent lung endogenous stem cells prospectively isolated from human lung tissue according to the cell surface expression of c-Kit (17) . The stem cells reportedly expressing c-Kit clonally proliferated and differentiated into both mature epithelial and endothelial lung cells, and completely replaced injured mice lung tissue by local injection (17) . However, the stemness of cells expressing c-Kit in situ is controversial (10, 18, 20, 27, 30, 37) , and the distribution and fate of c-Kit ϩ cells in human lung tissues are unknown.
With this background we aimed to clarify the origin and lineage of c-Kit ϩ cells in human lungs. Because a genetic lineage tracing method could not be applicable to human subjects, we traced c-Kit immunopositive cells in a series of developing human lung specimens at various gestational and postnatal ages. We also observed SCF immunopositive cells in identical lung sections to confirm the potential contribution of c-Kit signaling in human lung development.
MATERIALS AND METHODS
Patients and lung specimen handling. Human fetal lung tissues (n ϭ 16) were obtained from elective abortions at 13-20 gestational wk (GW) of normal pregnancy. Fetal lung specimens from 24 GW to term (n ϭ 13) and pediatric lung specimens (n ϭ 4) were retrieved from autopsy files at Tohoku University Hospital. Fetal age was estimated by the last menstrual date, body weight, and/or crown-rump length. None of the studied cases had pneumonia, pulmonary abnormalities, or severe congenital malformations. Human adult lung tissues (n ϭ 8) were obtained from surgical specimens at Tohoku University Hospital and Japanese Red-Cross Ishinomaki Hospital. Uninvolved peripheral lung tissues were used. Each studied case had normal histological appearance by hematoxylin-eosin staining. Characteristics of fetal and adult patients are described in Table 1 . The study protocol was approved by the Ethics Committee of Tohoku University School of Medicine, Sendai, and Japanese Red-Cross Ishinomaki Hospital, Ishinomaki, Japan.
Antibodies. A recent report demonstrated that mast cells of lungs consistently express c-Kit (2) . To distinguish mast cells from c-Kit ϩ fetal lung cells, we used double staining for c-Kit and mast cell tryptase, which is specifically expressed by human mast cells (39) . In addition, we used anti-CD34 antibody to identify the endothelial cells (42) ; and anti-␣-smooth muscle actin (SMA) antibody to identify smooth muscle cells, myofibroblasts (16, 25) , and the vascular bed of the pulmonary artery and pulmonary vein (12, 25) .
Immunohistochemistry. Immunohistochemistry of c-Kit or SCF was performed using the avidin-biotin complex method (Histofine SAB-PO kit or Histofine SAB-AP kit; Nichirei, Tokyo, Japan). Lung tissues were fixed with 10% formalin, embedded in paraffin, and CM, cardiac malformation; FH, fetal hydrops; GW, gestational weeks; HB, hepatoblastoma; HLH, hypoplastic left heart; IUD, intrauterine death; PDA, patent ductus arteriosus; RF, respiratory failure; SD, sudden death; TUC, torsion of umbilical cord; VSD, ventricular septum defect. sectioned at 3 m thickness. Sections were deparaffinized in a graded series of xylene and ethanol. After heat-induced antigen retrieval with Target Retrieval Solution, High pH (DAKO Japan, Tokyo, Japan), sections were treated with 10% normal goat serum for 30 min at room temperature. Sections were then incubated with a rabbit polyclonal anti-human c-Kit antibody (1:100; DAKO Japan) or a mouse monoclonal anti-human SCF antibody (1:400, clone G-3; Santa Cruz Biotechnology, Santa Cruz, CA) at 4°C overnight. After endogenous peroxidase activity was blocked with 0.3% H 2O2 in methanol, the sections were subsequently reacted with a goat anti-rabbit immunoglobulin G (IgG) secondary antibody followed by horseradish peroxidase-labeled streptavidin for 30 min at room temperature. The immune complex was visualized with 3,3=-diaminobenzidine (DAB) solution. Hematoxylin was used for counterstaining. Double staining of c-Kit and mast cell tryptase was performed as described below. After visualization with DAB, the sections were placed in 10 mM citric acid buffer (pH 6.0) and autoclaved at 121°C for 5 min to stop the first immunoreaction. After incubation with 10% normal rabbit serum, a mouse monoclonal anti-human mast cell tryptase antibody (1:4,000, clone AA1; Santa Cruz Biotechnology) was applied overnight. The sections were subsequently reacted with rabbit anti-mouse IgG and IgM secondary antibodies, followed by alkaline phosphatase-labeled streptavidin for 30 min at room temperature. Immunoreactivity of mast cell tryptase was visualized by the Vector Red substrate kit (Vector Laboratories, Burlingame, CA) in 0.1 M Tris·HCl (pH 8.3). Hematoxylin was used for counterstaining. Double staining using the combination of primary antibodies among the anti-c-Kit antibody, a mouse monoclonal anti-human-␣-SMA (1:100, clone 1A4; DAKO Japan), and a mouse monoclonal antihuman SCF antibody was performed as described above with appropriate secondary antibodies and color development. Negative control staining was performed, omitting primary antibodies with the same technique. Images were captured using a Nikon Eclipse microscope (Nikon, Tokyo, Japan).
Immunofluorescence microscopy. Deparaffinized sections were treated with heat-induced antigen retrieval. After nonspecific binding was blocked with 10% goat serum, combinations of the diluted primary antibodies against c-Kit (1:100, rabbit polyclonal; and 1:1,000, mouse monoclonal, clone X1; Abcam), CD45 (1:6,000, clone MEM-28; Abcam), CD34 (1:100, clone QBend10; DAKO Japan), proliferating cell nuclear antigen (PCNA) (1:200, clone PC10; DAKO Japan), SCF (1:400), phospho-c-src (1:10,000, phospho-tyrosine 530, clone H-3; Santa Cruz Biotechnology), and phosphor-Akt (1:50, phospho-serine 473, clone D9E; Cell Signaling Technology) were applied and incubated overnight at 4°C. All primary antibodies were detected using Alexa Fluor 488 goat anti-rabbit IgG (1:100, Molecular Probes, Carlsbad, CA), Alexa Fluor 488 goat anti-mouse IgG (1:100, Molecular Probes), Alexa Fluor 546 goat anti-rabbit IgG, Alexa Fluor 555 goat anti-mouse IgG (1:100, Molecular Probes), and Alexa Fluor 647 goat anti-mouse IgG (1:100, Molecular Probes). The sections were mounted using ProLong Gold Antifade Reagent with DAPI (Molecular Probes). The fluorescence signal was visualized by fluorescent microscopy at the appropriate wavelength for each secondary antibody on a Leica fluorescence microscope or an all-in-one type fluorescence microscope (BZ-9000; Keyence, Osaka, Japan) using BZ Analyzer software (Keyence).
Confocal laser scanning microscopy (CLSM). For confocal laser microscope scanning, paraffin-embedded lung tissues were cut at 15 m and thoroughly deparaffinized. After heat-induced antigen retrieval and incubation with 10% normal goat or donkey serum, combinations of the diluted primary antibodies against c-Kit (1:100), CD34 (1:100), vascular endothelial growth factor receptor 2 (VEGFR2) (1:20; R&D Systems), and Tie-2 (1:20; R&D Systems) were incubated on sections for 48 h at 4°C, followed by incubation with appropriate secondary antibodies including Alexa Fluor 488 goat anti-mouse IgG (1:100; Molecular Probes), Alexa Fluor 546 goat anti-rabbit IgG (1:100; Molecular Probes), Alexa Fluor 488 donkey anti-rabbit IgG (1:100; Molecular Probes), and Alexa Fluor 546 donkey anti-goat IgG (1:100; Molecular Probes) for 24 h at 4°C. TO-PRO 3 (Molecular Probes) was used for nuclear staining. Sections were examined on a Nikon C1 confocal imaging system. Excitation wavelengths included 488, 542, and 633 nm for Alexa Fluor 488, 546, and TO-PRO 3, respectively. Individual optical sections for different fluorogens (optical depth Ͻ0.5 m) were ob- tained, and stacked optical sections were merged using EZ-C1 software (Nikon).
Cell count and statistics. Photographs were captured under no less than ϫ400 magnification. Cells were counted with Image-J software using at least five different optical fields in each lung samples. Statistical analysis was performed using GraphPad Prism software (GraphPad, La Jolla, CA). One-way ANOVA with a Tukey's multiple comparison test was performed where appropriate.
RESULTS
Traditionally, human lung development is divided into five stages: embryonic (up to 8 GW), pseudoglandular (8 -16 GW), canalicular (17-27 GW), saccular (28) (29) (30) (31) (32) (33) (34) (35) , and alveolar (36 GW to term). These developmental stages are categorized on the basis of gross histological appearance and stage-specific branching morphogenesis of both bronchi and pulmonary vessels. During the embryonic and pseudoglandular phases, all preacinar airways develop via the progressive branching of lung buds that originate from the outgrowth of the foregut. Pulmonary vessel formation is slowly completed, and all preacinar arteries and veins are present by 17 GW using the airways as a template (14) . Further division of bronchial trees and pulmonary vessels takes place during the canalicular phase. Immature alveolar sacs are present from the saccular phase as double capillary layers. These double capillary layers protrude into the alveolar cavities to form secondary septa and finally fuse to give rise to single capillary layers of the adult form. This process, called alveolarization, begins at 36 GW and continues for several years after birth. The fetal lung specimens used in this study encompassed all developmental stages except the embryonic phase. We demonstrate the stepwise expression of c-Kit and the spatial distribution of c-Kit and SCF in the developing human lung.
c-Kit expression in lung mesenchyme. Immunohistochemical staining revealed c-Kit ϩ cells in the peripheral lung from 13 GW (Fig. 1A) . Most c-Kit ϩ cells were spindle shaped and scattered in the lung mesenchyme. We employed double staining to identify the cell type of the c-Kit ϩ cells. These c-Kit ϩ cells did not express either mast cell tryptase (Fig. 1A) or ␣-SMA (Fig. 1B) , and most of the c-Kit ϩ cells were negative for CD45 (Fig. 1, C-E) . Immunoexpression of c-Kit was confirmed using a rabbit polyclonal antibody and a mouse monoclonal antibody, which react with amino acids 963 to 976 at the cytoplasmic C-terminal part of human c-Kit, and amino acids 41-140 of human c-Kit, respectively (Fig. 1, F-H) .
Double immunofluorescence by CLSM demonstrated that these c-Kit ϩ cells coexpressed endothelial cell markers; CD34 (Fig. 2, A-C) , VEGFR2 (Fig. 2, F-H) , and Tie-2 (Fig. 2, I-K 
/CD34
ϩ cells in the pseudoglandular phase (Fig. 2, D and E) . Some of the c-Kit
ϩ cells showed a closed-end tube formation that did not contain hematopoietic cells (Fig. 2D) , and c-Kit 
Distribution of c-Kit expression in developing human lungs.
During embryogenesis, c-Kit ϩ cells were consistently observed in the peripheral lung mesenchyme (Fig. 3, A-C) . These c-Kit ϩ cells appeared to form a network alongside the branching lung buds (Fig. 3A) in the canalicular phase. Double staining demonstrated that bright c-Kit expression was exclusively observed in the capillary vasculature and not in the central pulmonary vessels accompanied by the ␣-SMA ϩ vascular bed (Fig. 3, A-C) . From the canalicular phase, the connection of c-Kit ϩ cells with the central pulmonary artery and pulmonary vein was observed (Fig. 3, D and E) . The direct connection of kit ϩ /CD34 ϩ cells and c-Kit Ϫ /CD34 ϩ large pulmonary vessels was consistently observed during the canalicular and alveolar phases (Fig. 3F) .
On the other hand, epithelial cells of lung buds did not express c-Kit (Fig. 1, A and B) . In the earliest lung tissue studied, c-Kit expression of epithelial cells was exclusively observed in tracheal airway epithelial cells (Fig. 4A) . c-Kit expression of tracheal and bronchial epithelial cells was consistently observed after the canalicular phase (Fig. 4B) . From the saccular phase, conducting airway epithelial cells expressed c-Kit (Fig. 4, C and D) . c-Kit expression of epithelial cells was homogenous during lung development, and no specific epithelial population was identified by c-Kit expression. In addition, c-Kit ϩ /tryptase ϩ mast cells were observed alongside the central airway epithelial cells (Fig. 4) . c-Kit ϩ /tryptase ϩ mast cells were not detected in fetal peripheral lung tissues (data not shown).
Increasing c-Kit ϩ cells according to gestational stages. Along with gestational ages, the percentage of c-Kit ϩ cells among mesenchymal cells consistently increased from the pseudoglandular (17%) to alveolar phase (24%) with statistical significance (Fig. 5A) . The percentage of c-Kit ϩ cells among entire CD34 ϩ cells, always above 90%, indicated that almost all increasing c-Kit ϩ cells were endothelial cells (Fig. 6A) . In addition, the number of c-Kit ϩ cells per 1 mm 2 of fetal lung tissues was significantly higher in the canalicular phase ( doglandular phase was consistent with the observation (Fig.  6, B-E) .
Spatial distribution of SCF and expression of phosphorylated proteins downstream of c-Kit signaling.
From the pseudoglandular phase to the canalicular phase, SCF-expressing cells were observed immediately beneath the lung buds and within the lung mesenchyme (Fig. 7, A and B) . As indicated by double immunofluorescence, SCF ϩ mesenchymal cells were different from c-Kit ϩ endothelial cells. In the canalicular phase, SCF-expressing mesenchymal cells were closely associated with c-Kit ϩ capillary endothelial cells (Fig. 7B) . The percentage of SCF-expressing cells among total lung cells were significantly increased in the canalicular phase (Fig. 7C) in accordance with the increase in c-Kit ϩ cells. The phosphorylation status of c-src and Akt downstream of c-Kit signaling was also confirmed using phospho-specific antibodies. Hypophosphorylation of c-src tyrosine 530 in c-Kit ϩ cells suggested activation of c-src (Fig. 7, D-F) . Furthermore, serine 473 of Akt in c-Kit ϩ cells was consistently phosphorylated during the pseudoglandular and canalicular phases (Fig. 7, G-I; and data not shown) .
c-Kit and SCF expression in the postnatal human lung. A number of c-Kit
ϩ cells was observed in all pediatric lungs studied (Fig. 8, A and B; data not shown). In the pediatric cases, the heterogeneous expression of c-Kit was observed in the lung parenchyma and alveolar walls (Fig. 8, A and C) . In the lung of a 6-yr-old boy, presenting mature single capillary alveolar walls, c-Kit, and CD34 coexpression were clearly detected (Fig. 8, G-I) . The number of c-Kit ϩ cells in postnatal lung tissue was significantly decreased during lung maturation (about 20% of lung cells in pediatric lungs to less than 1% in adult lungs; Fig. 8A ). In addition, most c-Kit ϩ cells in adult lungs also expressed mast cell tryptase, a specific marker for mast cells (Fig. 8B) . The number of mast cells in the lung parenchyma was significantly increased after birth. They were observed in the perivascular space, lung parenchyma, and alveolar walls (Fig. 8, C-F) . SCF expression was consistently observed in alveolar macrophages and in some mesenchymal cells in the lung parenchyma and large pulmonary vessels after birth (Fig. 9) . In this study, c-Kit ϩ /CD34 ϩ cells could not be detected in adult lungs (data not shown).
DISCUSSION
To our knowledge, this is the first comprehensive observational study of the expression of c-Kit and SCF in the devel- oping human lung using immunohistochemistry. Our results demonstrated for the first time that the lung mesenchymal endothelial progenitor population expresses c-Kit. Because c-Kit ϩ cells in the early developing lung mesenchyme coexpress CD34, VEGFR2, and Tie-2, all markers of endothelial cells, these c-Kit ϩ cells are likely endothelial cells (25) . Absence of CD45 and mast cell tryptase expression in most c-Kit ϩ cells suggests a nonhematopoietic origin of c-Kit ϩ cells (Fig. 1) . The reactivity of c-Kit ϩ cells to the anti-PCNA antibody suggests that these cells are actively dividing (Fig. 6) . Among the fetal lung tissue studied, c-Kit expression of the developing lung mesenchyme was consistently accompanied by CD34 expression (Fig. 6 ). On the other hand, epithelial cells in lung buds did not express c-Kit in the early stage of lung development. c-Kit expression of postnatal lung cells was distinct in mast cells, and c-Kit expression in lung epithelial and endothelial cells was diminished in adult lungs. These observations indicated that c-Kit expression could solely identify the potent endothelial progenitor population only in the early stage of lung development. In the late stage of lung development and adult lungs, the c-Kit-positive population included a mixture of already differentiated multiple cell types, including mast cells.
The reported c-Kit expressing human lung stem cells demonstrated their multipotency to differentiate into both epithelial and endothelial lineages in an experimental model (17) . However, our present data clearly demonstrate that c-Kit expressing cells already had been initiated with endothelial lineage in vivo. In addition, it is generally accepted that lung epithelial and endothelial cells originate from different fetal lung cell populations; lung buds and lung mesenchyme, respectively (29) . Taken together, to assume the presence of fully multipotent c-Kit expressing lung stem cells in human lung in situ, is controversial.
Additional (9, 13, 38) . c-Kit ϩ cells were identified as tissueresident endothelial progenitor cells in vivo (4, 36) . Previous studies have identified c-Kit expressing cells in developing lung mesenchyme both in rodent (4) and human fetuses (6) . In an observation of human fetal lungs, a decreased number of c-Kit ϩ cells is believed to have an association with alveolar capillary dysplasia (6) . Consistent with these previous investi- gations, our results implicate an important role for c-Kit signaling in lung vascular development and VEGF (25) .
Although previous investigations were limited, they were able to implicate the association of c-Kit signaling and lung tissue homeostasis. During early stages of lung transplantation, recipients have exhibited marked elevation of SCF in the bronchoalveolar lavage fluid, and c-Kit expression in the bronchial epithelial cells was also observed, suggesting that c-Kit signaling would support the epithelial repair process after lung transplantation (7) . In addition, recent investigations have demonstrated that mice bearing a functional variant of c-Kit spontaneously developed an emphysema-like lung (24) . The study also demonstrated that c-Kit signaling blockade by imatinib mesylate inhibited proliferation of mice lung epithelial cells. Those investigations and bronchial epithelial c-Kit expression in the developing human lungs demonstrated in this study allow us to speculate that c-Kit signaling is also important for human lung epithelial cell maintenance.
This study unexpectedly provided important information related to the origin of the distal pulmonary vasculature. Because the pulmonary artery and pulmonary vein did not show c-Kit expression (Fig. 3, D and E) , we hypothesized that c-Kit ϩ /CD34 ϩ endothelial cells would directly bring vasculature from the mesenchyme by means of vasculogenesis (33) . To confirm the hypothesis, we employed a 3D CLSM observation. The high-resolution 3D reconstruction views obtained by the serial stacking of optical sections demonstrated that the close-ended endothelial capsule coexpressed c-Kit and CD34. The c-Kit ϩ /CD34 ϩ tubes did not appear to contain hematopoietic cells or to coalesce with each other (Fig. 1, E and F; and Supplementary Movies). This is identical to the morphological description of vasculogenesis in vivo (41) . In addition, c-Kit ϩ / CD34 ϩ cells appeared to connect to the large pulmonary vessels to establish pulmonary circulation. These observations indicate that c-Kit ϩ /CD34 ϩ cells could be so-called residual lung angioblasts (1, 8, 12) . Previous investigations postulated two conflicting models for early pulmonary vascular development; a vasculogenesis model (32, 35) , and a distal angiogenesis model. According to the immunohistochemical expression pattern of c-Kit demonstrated in this study, distal pulmonary vasculature is believed to originate from residual lung mesenchymal cells expressing c-Kit by means of vasculogenesis.
The developmental distribution of c-Kit and SCF in human fetal and postnatal lungs is illustrated in Fig. 10 : A: c-Kit ϩ cells develop in the distal pulmonary vasculature; B: c-Kit ϩ vascular tubes connect to the central pulmonary vessels or closely associate with mesenchymal cells expressing SCF; C: from the beginning of alveolarization, c-Kit ϩ capillary cells protrude into the alveolar cavity for alveolar septa formation; D: in postnatal life, c-Kit ϩ /CD34 ϩ cells reside in the pulmonary vasculature for several years and then E: lose c-Kit expression. Contrasting SCF expression was observed in mesenchymal cells, the vascular bed of the central pulmonary vessels, and alveolar macrophages. The limitation of this study is its descriptive nature of immunohistochemistry using formalin-fixed materials. No interventional method was employed. However, using two different c-Kit antibodies, the possibility of false negative and false positive for c-Kit expression was believed to be minimized. In addition, double staining using phosphospecific antibodies suggest activated c-Kit signaling in c-Kit ϩ cells. Therefore, we believe the spatial and temporal expression pattern of c-Kit and SCF in human lungs described in this study warrants further investigation of the roles of c-Kit signaling in lung development.
